Latest Interstitial lung disease Stories
Mercury Insurance Open's Kitty Winterhalter Lopez Recently Diagnosed with Pulmonary Fibrosis CARLSBAD, Calif., Aug. 5, 2011 /PRNewswire-USNewswire/ -- Kitty Winterhalter has long helped professional tennis tournaments become successful. This year, she's asking a pro tennis tournament to help her.
BRISBANE, Calif., Aug. 4, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2011.
BRISBANE, Calif., July 28, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that it will release its second quarter 2011 financial results on Thursday, August 4, 2011. A live conference call and webcast will be hosted by InterMune at 4:30 p.m.
Awards Given for Research, Humanitarian and Advocacy Efforts CULVER CITY, Calif., July 25, 2011 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) proudly announces the winners of its three annual awards for distinguished service.
Patients with idiopathic pulmonary fibrosis (IPF) who report treatment for gastroespophageal reflux (GER) appear to have longer survival than IPF patients who are not treated for GERD.
Landmark Bill Introduced in Senate and House Would Create National Patient Registry, Increase Public Awareness of Lethal Lung Disease WASHINGTON, July 12, 2011 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act (PFREA) has been introduced in the Senate by Senators Chris Coons (D-DE) and Mike Crapo (R-ID) in the U.S.
Landmark Legislation Will Coordinate and Expand National Research on Pulmonary Fibrosis CHICAGO, July 12, 2011 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) announced today the re-introduction of the Pulmonary Fibrosis Research Enhancement Act (PFREA).
BRISBANE, Calif., July 7, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).